Publications by authors named "Dolores Fernandez Jimenez"
Platelet Responses After Tapering and Discontinuation of Fostamatinib in Patients with Immune Thrombocytopenia: A Continuation of the Fostasur Study.
J Clin Med
October 2024
Article Synopsis
- Fostamatinib is an approved treatment for adults with chronic immune thrombocytopenia (ITP) but there's limited research on tapering doses and achieving remission after stopping the drug.
- A study involving 61 patients examined the safety and effectiveness of fostamatinib during and after dose tapering, noting that complete platelet response was typically achieved within 28 days.
- Results showed that most patients maintained platelet counts above 100 × 10/L after discontinuation, with a low relapse rate, suggesting that tapering could lead to sustained remission, though further research on tapering strategies is needed.
Fostamatinib, a recently approved Syk inhibitor used in adult primary immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However, clinical trial results may not be similarly reproduced in clinical practice. Here, 138 patients with ITP (both primary and secondary) from 42 Spanish centers who had been treated with fostamatinib were evaluated prospectively and retrospectively.
View Article and Find Full Text PDFImmune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second-line treatment for ITP. Real-world data on fostamatinib are lacking.
View Article and Find Full Text PDFObjectives: To verify the reliability and clinical benefits of the coagulation tests made by a point of care device in newborn admitted to a neonatal unit.
Design: We made a statistical comparison between results obtained by the point of care device versus conventional laboratory analysis.
Setting: Level 3 neonatal unit.